Genomes and Genes
Summary: An antibiotic substance derived from Penicillium stoloniferum, and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1301)
Publications356 found, 100 shown here
- Review of major clinical trials with mycophenolate mofetil in renal transplantationGaetano Ciancio
Department of Surgery, Division of Transplantation, Lillian Jean Kaplan Renal Transplant Center, Leonard M Miller School of Medicine, University of Miami, Miami, FL 33101, USA
Transplantation 80:S191-200. 2005....
- Reduced exposure to calcineurin inhibitors in renal transplantationHenrik Ekberg
Lund University, Malmo, Sweden
N Engl J Med 357:2562-75. 2007..Immunosuppressive regimens with the fewest possible toxic effects are desirable for transplant recipients. This study evaluated the efficacy and relative toxic effects of four immunosuppressive regimens...
- Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritisGerald B Appel
Department of Nephrology, Columbia University, New York, New York, USA
J Am Soc Nephrol 20:1103-12. 2009..Although most patients in both treatment groups experienced clinical improvement, the study did not meet its primary objective of showing that MMF was superior to IVC as induction treatment for lupus nephritis...
- Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trialKlemens Budde
Department of Nephrology, Charite University, Berlin, Germany
Lancet 377:837-47. 2011..Immunosuppression based on the mammalian-target-of-rapamycin inhibitor everolimus was assessed as a strategy for elimination of calcineurin-inhibitor exposure and optimisation of renal-graft function while maintaining efficacy...
- Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivoQiuwei Pan
Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, Netherlands
Hepatology 55:1673-83. 2012b>Mycophenolic acid (MPA) is a highly effective immunosuppressant that has broad antiviral activity against different viruses and can act in synergy with interferon-α (IFN-α) on hepatitis C virus (HCV) replication...
- Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritisEllen M Ginzler
Division of Rheumatology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
N Engl J Med 353:2219-28. 2005..Since anecdotal series and small, prospective, controlled trials suggest that mycophenolate mofetil may be effective for treating lupus nephritis, larger trials are desirable...
- Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis TrialFrédéric A Houssiau
Rheumatology Department, Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Saint Luc University Hospital, Brussels 1200, Belgium
Ann Rheum Dis 69:2083-9. 2010..This investigator-initiated randomised trial tested whether mycophenolate mofetil (MMF) was superior to azathioprine (AZA) as maintenance treatment...
- Mycophenolic acid inhibits the phosphorylation of NF-kappaB and JNKs and causes a decrease in IL-8 release in H2O2-treated human renal proximal tubular cellsMichele Andreucci
Chair of Nephrology, Magna Graecia University, Catanzaro, Italy
Chem Biol Interact 185:253-62. 2010..Interleukin (IL)-8 production also increased upon H(2)O(2) stimulation. Pre-incubation of the cells with mycophenolic acid (MPA) resulted in reduced phosphorylation of both JNKs and NF-kappaB, and reduced IL-8 release in H(2)O(2)-..
- The inhibitors of nucleotide biosynthesis leflunomide, FK778, and mycophenolic acid activate hepatitis B virus replication in vitroKarin Hoppe-Seyler
Molecular Therapy of Virus Associated Cancers, German Cancer Research Center DKFZ, Heidelberg, Germany
Hepatology 56:9-16. 2012..This activity is shared by mycophenolic acid (MPA), an inhibitor of purine biosynthesis...
- Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity?W Arns
Cologne General Hospital, Merheim Medical Center, Cologne, Germany
Transplant Proc 39:88-93. 2007b>Mycophenolic acid (MPA), a reversible inhibitor of inosine 5''-monophosphate dehydrogenase (IMPDH), selectively inhibits T- and B-cell proliferation. MPA exposure correlates inversely with the risk of acute rejection...
- Versatile enzyme expression and characterization system for Aspergillus nidulans, with the Penicillium brevicompactum polyketide synthase gene from the mycophenolic acid gene cluster as a test caseBjarne G Hansen
Technical University of Denmark, Department of Systems Biology, Center for Microbial Biotechnology, Building 223, 2800 Kgs Lyngby, Denmark
Appl Environ Microbiol 77:3044-51. 2011..expressing mpaC or mutated mpaC genes unequivocally demonstrated that mpaC indeed encodes a polyketide synthase that produces the first intermediate in the production of the medically important immunosuppressant mycophenolic acid.
- Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNAMichael S Diamond
Division of Infectious Diseases, School of Public Health, University of California, Berkeley 94720 7360, USA
Virology 304:211-21. 2002..We assessed the ability of mycophenolic acid (MPA), a drug currently used as an immunosuppressive agent, to inhibit dengue virus (DV) antigen expression, ..
- Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipientsChristine E Staatz
School of Pharmacy, University of Queensland, Brisbane, Queensland, Australia
Clin Pharmacokinet 46:13-58. 2007..b>Mycophenolic acid (MPA) is the active drug moiety...
- Rapamycin and MPA, but not CsA, impair human NK cell cytotoxicity due to differential effects on NK cell phenotypeD N Eissens
Department of Laboratory Medicine, Laboratory of Medical Immunology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Am J Transplant 10:1981-90. 2010Cyclosporin A (CsA), rapamycin (Rapa) and mycophenolic acid (MPA) are frequently used for GVHD prophylaxis and treatment after allogeneic stem cell transplantation (SCT)...
- Calcineurin inhibitor-free protocols: risks and benefitsA G Barbari
Saudi J Kidney Dis Transpl 18:1-23. 2007....
- Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trialMarkus Guba
Department of Surgery, Munich University Hospital, Campus Grosshadern, Munich, Germany
Transplantation 90:175-83. 2010..De novo sirolimus in calcineurin inhibitor-free regimens, although potentially useful to improve early renal function, are complicated by various drug-related side effects...
- Mycophenolic acid and thiazole adenine dinucleotide inhibition of Tritrichomonas foetus inosine 5'-monophosphate dehydrogenase: implications on enzyme mechanismL Hedstrom
Department of Pharmaceutical Chemistry, School of Pharmacy, University of California, San Francisco 94143
Biochemistry 29:849-54. 1990..b>Mycophenolic acid is also an uncompetitive inhibitor versus IMP and noncompetitive versus NAD...
- Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantationDirk R J Kuypers
Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium
Clin J Am Soc Nephrol 5:341-58. 2010With the increasing use of mycophenolic acid (MPA) in solid organ transplantation, the need for more accurate drug dosing has become evident...
- Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept studyY Lebranchu
Service Nephrologie Immunologie Clinique, CHRU Tours, EA 4245, University Francois Rabelais, Tours, France
Am J Transplant 9:1115-23. 2009..Significantly, more patients in the SRL group reported aphthous, diarrhea, acne and high triglyceride levels. Conversion CsA to SRL 3 months after transplantation combined with MMF is associated with improvement in renal function...
- One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipientsH T Silva
Hospital do Rim E Hipertansã, Sao Paulo, Brazil
Am J Transplant 7:595-608. 2007..The results support the safety and efficacy of tacrolimus in combination with MMF, corticosteroids and basiliximab induction, as well as XL as a safe and effective once-daily dosing alternative...
- Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritisJai Radhakrishnan
Department of Medicine, Columbia University Medical Center, 622 W 168th St, New York, NY 10032, USA
Kidney Int 77:152-60. 2010..Hence we found that the response to MMF as induction treatment of patients with class V LN appears to be no different from that to IVC...
- Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liverFederico Mingozzi
Division of Hematology and Center for Cellular and Molecular Therapeutics, The Children s Hospital of Philadelphia, PA 19104, USA
Blood 110:2334-41. 2007....
- Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycinMartin J Hoogduijn
Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
Transplantation 86:1283-91. 2008..The molecular targets of these drugs are expressed in MSC, but the effect of their inhibition on MSC functioning is unknown...
- Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapyHaiyan Jiang
Bayer HealthCare Pharmaceuticals, 800 Dwight Way, Berkeley, CA 94710, USA
Blood 108:3321-8. 2006..These findings enable a clinical study to assess the effects of immunomodulation on long-term FIX expression in patients with hemophilia B...
- Malignancy after transplantationJoseph F Buell
Israel Penn International Transplant Tumor Registry, University of Cincinnati, Cincinnati, OH 45267 0558, USA
Transplantation 80:S254-64. 2005..Long-term data are needed to determine if the use of these agents will ultimately lower the mortality due to malignancy for transplant recipients...
- Updates on the treatment of lupus nephritisAndrew S Bomback
Department of Medicine, Division of Nephrology, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
J Am Soc Nephrol 21:2028-35. 2010..Here, we review recent additions to the growing body of literature on how to most effectively treat lupus nephritis with the least amount of toxicity. We discuss new treatment strategies currently being explored in clinical trials...
- Overexpression of a cloned IMP dehydrogenase gene of Candida albicans confers resistance to the specific inhibitor mycophenolic acidG A Köhler
Department of Stomatology, University of California San Francisco, 94143 0422, USA
J Bacteriol 179:2331-8. 1997..Growth of wild-type (sensitive) C. albicans cells is inhibited at 1 microg of mycophenolic acid (MPA), a specific inhibitor of IMP dehydrogenases, per ml, whereas transformants hosting a plasmid with the ..
- Inhibition of dengue virus replication by mycophenolic acid and ribavirinRatree Takhampunya
Department of Microbiology and Immunology, Georgetown University School of Medicine, 3900 Reservoir Road, Washington, DC 20057, USA
J Gen Virol 87:1947-52. 2006..The effects of mycophenolic acid (MPA) and ribavirin (RBV) on DEN replication in monkey kidney (LLC-MK2) cells were examined. MPA (IC(50)=0...
- Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetilWolfgang Arns
Merheim Medical Center, Cologne General Hospital, Cologne, Germany
Clin Transplant 19:199-206. 2005b>Mycophenolic acid (MPA), the active moiety of mycophenolate mofetil (MMF), is routinely used as an adjunct immunosuppressant therapy in renal transplantation...
- Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alphaScot D Henry
Department of Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands
Gastroenterology 131:1452-62. 2006..Cyclosporine A (CsA) specifically inhibits HCV replication through blocking the viral RNA polymerase enzyme NS5B. In this study, we investigated the effect of mycophenolic acid (MPA) and other immunosuppressants on HCV replication.
- Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year studyKlemens Budde
University Hospital Charite, Berlin, Germany
Am J Transplant 4:237-43. 2004..8%; MMF 4.9%; p=NS) were observed in both groups. In conclusion, renal maintenance patients can be converted from MMF to EC-MPS without compromising the safety and efficacy profile associated with MMF...
- New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantationHylke de Jonge
Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium
Ther Drug Monit 31:416-35. 2009..these new insights for the calcineurin inhibitors (CNIs) cyclosporine and tacrolimus and the antimetabolite mycophenolic acid (MPA) and will discuss the possible consequences...
- Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycinSebastiaan Heidt
Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
Transplantation 86:1292-300. 2008..In general, humoral rejection is treated with standard immunosuppressive drugs. The direct effect of these immunosuppressive drugs on B cells is not well known...
- Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literatureWolfgang Arns
Transplant Department, Merheim Medical Center, Cologne General Hospital, Cologne, Germany
Transplantation 82:1004-12. 2006..MMF) has conventionally been administered at a fixed dose without routinely monitoring blood levels of mycophenolic acid (MPA), the active metabolite...
- Effects of mycophenolic acid on endothelial cellsYanfei Huang
Research Institute of Nephrology, Jingling Hospital, Nanjing University School of Medicine, Nanjing, 210002, China
Int Immunopharmacol 5:1029-39. 2005..In the present study, the effect of mycophenolic acid (MPA), the active metabolite of MMF, on human umbilical vein endothelial cells (HUVECs) was investigated...
- Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantationH Ekberg
Lund University, Malmo, Sweden
Am J Transplant 9:1876-85. 2009....
- Mycophenolic acid suppresses granulopoiesis by inhibition of interleukin-17 productionSibylle von Vietinghoff
Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA
Kidney Int 78:79-88. 2010b>Mycophenolic acid is a commonly used immunosuppressant after organ transplantation and in autoimmune diseases; however, myelosuppression is a major complication despite its largely favorable side-effect profile...
- Overexpression of inosine 5'-monophosphate dehydrogenase type II mediates chemoresistance to human osteosarcoma cellsJorg Fellenberg
Department of Experimental Orthopedics, Orthopedic University Hospital Heidelberg, Heidelberg, Germany
PLoS ONE 5:e12179. 2010..The aim of this study was to provide evidence for direct involvement of IMPDH2 in the development of chemoresistance...
- Mycophenolic acid inhibits activation of inducible nitric oxide synthase in rodent fibroblastsDj Miljkovic
Institute for Biological Research Sinisa Stankovic, School of Medicine, University of Belgrade, Belgrade, Yugoslavia
Clin Exp Immunol 132:239-46. 2003..We here investigated the effect of bioactive MMF compound mycophenolic acid (MPA) on iNOS-mediated NO synthesis in fibroblasts, which are important source of NO in rheumatoid arthritis ..
- Mycophenolate mofetil (MMF): firing at the atherosclerotic plaque from different angles?Sander I van Leuven
Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
Cardiovasc Res 69:341-7. 2006..The present review provides an overview of the potential anti-atherogenic properties of MMF...
- Effects of mycophenolic acid on human fibroblast proliferation, migration and adhesion in vitro and in vivoC Morath
Department of Nephrology, University of Heidelberg, Germany
Am J Transplant 8:1786-97. 2008b>Mycophenolic acid (MPA) is a potent inhibitor of the inosine monophosphate dehydrogenase and used as an immunosuppressive drug in transplantation. MPA inhibits proliferation of T- and B-lymphocytes by guanosine depletion...
- Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplantGerhard Opelz
Transplantation 86:371-6. 2008..Data are scarce concerning the impact of maintenance immunosuppression dose reductions posttransplant...
- Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trialMatthew R Weir
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
Kidney Int 79:897-907. 2011..Thus, compared with MMF/CNI treatment, a 2-year regimen of MMF/SRL resulted in similar measures of renal function but with fewer deaths and a trend to less BPAR and graft loss...
- Prolonged depletion of guanosine triphosphate induces death of insulin-secreting cells by apoptosisG Li
Medical Service, Middleton Veterans Administration Hospital, Madison, Wisconsin 53705, USA
Endocrinology 139:3752-62. 1998Inhibitors of IMP dehydrogenase, such as mycophenolic acid (MPA) and mizoribine, which deplete cellular GTP, are used clinically as immunosuppressive drugs...
- A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic Acid and tacrolimus early after renal transplantationFlora Tshinanu Musuamba
Louvain Drug Research Institute, Louvain Centre for Toxicology and applied Pharmacology, LDRI PKDM B1 73 13, Av E Mounier 73, 1200 Bruxelles, Belgique
J Clin Pharmacol 52:1833-43. 2012b>Mycophenolic acid (MPA) and tacrolimus (TAC) are immunosuppressive agents used in combination with corticosteroids for the prevention of acute rejection after solid organ transplantation...
- Mycophenolate mofetil inhibits hepatitis C virus replication in human hepatic cellsLi Ye
Center for Animal Experiment, ABSL 3 Laboratory, Wuhan University, Hubei 430071, China
Virus Res 168:33-40. 2012..It is of interest to further determine whether MMF is indeed beneficial for HCV-infected transplant recipients in future clinical studies...
- Simultaneous determination of ochratoxin A, mycophenolic acid and fumonisin B(2) in meat productsLouise Marie Sørensen
Department of Systems Biology, Technical University of Denmark, Building 221, 2800, Lyngby, Denmark
Anal Bioanal Chem 398:1535-42. 2010Here we present a method for simultaneous determination of the fungal metabolites mycophenolic acid, ochratoxin A (OTA) and fumonisin B(2) (FB(2)) in meat products...
- Determination of mycophenolic acid in human plasma by high-performance liquid chromatographyV Srivatsan
Bioanalytical Department, Lambda Therapeutic Research Pvt Ltd, 42 Premier House 1, Gandhinagar Sarkhej Highway, Bodakdev, Ahmedabad 380 054, India
J Chromatogr A 1031:259-64. 2004..validation and evaluation of high-performance liquid chromatography (HPLC) method for quantifying mycophenolic acid in human plasma is described...
- Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) miceSander I van Leuven
Department of Medicine Division of Cardiovascular Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
Ann Rheum Dis 71:408-14. 2012..The current study aims to determine the benefit of lymphocyte inhibition on reducing the atherosclerotic burden in SLE-susceptible LDLr-deficient mice...
- Mycophenolate mofetil impairs transduction of single-stranded adeno-associated viral vectorsPaula S Montenegro-Miranda
Tytgat Institute for Liver and Intestinal Research, Academic Medical Center, 1105 BK Amsterdam, The Netherlands
Hum Gene Ther 22:605-12. 2011..In fact, clinical relevant concentrations of mycophenolic acid (MPA), the active compound of MMF, also impair the transduction of HEK-293T cells by ssAAV...
- The effect of mycophenolate mofetil and azathioprine dose on renal allograft outcome in the United kingdomSapna Shah
Centre for Translational Medicine and Therapeutics, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, London, United Kingdom
Transplantation 86:1035-42. 2008..The consequences, however, of dose reduction of mycophenolate mofetil relative to azathioprine have not been reported...
- Impact of mycophenolic acid on the functionality of human polymorphonuclear neutrophils and dendritic cells during interaction with Aspergillus fumigatusMarkus Mezger
Medizinische Klinik II, Universitat Wurzburg, 97070 Wurzburg, Germany
Antimicrob Agents Chemother 52:2644-6. 2008b>Mycophenolic acid (MPA) is used clinically to prevent graft rejection but may increase the risk of fungal infection...
- Randomized trial of immunosuppressive regimens in renal transplantationGiselle Guerra
Department of Medicine, Division of Nephrology, University of Miami Miller School of Medicine, P O Box 012440 R 440, Miami, FL 33101, USA
J Am Soc Nephrol 22:1758-68. 2011..Taken together, these results suggest that maintenance therapy with tacrolimus/MMF is more favorable than either tacrolimus/sirolimus or cyclosporine/sirolimus...
- Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activityM L Ritter
Department of Medicine, Division of Infectious Diseases, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York 10461, USA
Transpl Infect Dis 11:290-7. 2009..A thorough understanding of the functions of MMF on the immune system and interaction with infectious pathogens could be helpful in implementing preventative strategies against opportunistic infections in transplant patients...
- Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipientsP Massari
Servicio de Nefrologia, Hospital Privado Centro Médico, Cordoba, Argentina
Transplant Proc 37:916-9. 2005..The requirement for EC-MPS dose reduction to manage AEs was relatively low. Use of EC-MPS is a valid alternative for renal transplant recipients receiving maintenance MMF treatment...
- Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipientsHoward J Eisen
Division of Cardiology, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102 1192, USA
J Heart Lung Transplant 24:517-25. 2005..This study reports the 36-month results of a randomized, double-blind, active-controlled trial of mycophenolate mofetil (MMF) vs azathioprine (AZA) in heart transplant patients...
- Impact of gastrointestinal-related side effects on mycophenolate mofetil dosing and potential therapeutic strategiesSuphamai Bunnapradist
David Geffen School of Medicine, Department of Medicine, Division of Nephrology, Los Angeles, CA 90095 7306, USA
Clin Transplant 22:815-21. 2008..In conclusion, monitoring of GI complications is essential following renal transplantation, and maintaining adequate mycophenolic acid exposure should be a priority when considering treatment options.
- Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipientsGerardo Machnicki
Novartis Pharmaceuticals, East Hanover, New Jersey, USA
Pharmacoeconomics 26:951-67. 2008..This analysis was undertaken to assess the 3-year economic and clinical impact of mycophenolate mofetil dosage modifications or discontinuation following post-transplant GI events compared with no dosage modification...
- Gastrointestinal symptoms impair quality of life in Italian renal transplant recipients but are under-recognized by physiciansClaudio Ponticelli
Nephrology and Dialysis Unit, Scientific Institute Humanitas, Rozzano, Milano, Italy
Transpl Int 23:1126-34. 2010..816; P<0.0001). Gastrointestinal symptoms are frequent in renal transplant patients, are under-evaluated by physicians and may adversely impact on patient QOL...
- Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipientsH Tedesco Silva
Hospital do Rim e Hipertensao, Sao Paulo, Brazil
Am J Transplant 10:1401-13. 2010..5 or 3.0 mg/day (target troughs 3-8 and 6-12 ng/mL, respectively) with reduced-exposure CsA, or mycophenolic acid (MPA) 1.44 g/day plus standard-exposure CsA. Patients received basiliximab +/- corticosteroids...
- Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipientsMatthew Cooper
Division of Transplantation, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Transplantation 88:514-20. 2009....
- Outcomes in patients with active lupus nephritis requiring immunosuppressives who never received cyclophosphamideMurray B Urowitz
University of Toronto Lupus Clinic, Toronto Western Hospital, Toronto, Ontario, Canada
J Rheumatol 34:1491-6. 2007..To assess outcomes in patients with lupus nephritis treated with immunosuppressives compared to those treated with cyclophosphamide in a cohort study and in a matched cohort study...
- Illumina-microarray analysis of mycophenolic acid-induced cell death in an insulin-producing cell line and primary rat islet cells: new insights into apoptotic pathways involvedYun Jong Park
The Research Institute for Transplantation, Yonsei University College of Medicine, Seoul, Republic of Korea
Cell Signal 22:1773-82. 2010b>Mycophenolic acid (MPA), widely used to prevent organ transplant rejection, may induce toxicity and impair function in beta-cells. Mechanisms of MPA-induced cell death have not been fully explored...
- Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisalNeal M Davies
Nephrol Dial Transplant 22:2440-8. 2007..The effects of MMF and EC-MPS are likely mediated via the active metabolite mycophenolic acid (MPA)...
- Dissection of the molecular basis of mycophenolate resistance in Saccharomyces cerevisiaeM Harley Jenks
Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA
Yeast 22:1181-90. 2005..Although Imd2 is 92% identical to Imd3, it is the only S. cerevisiae IMPDH that is resistant to mycophenolic acid in vitro and is the only one of the four that supports drug-resistant growth. Thus, S...
- Impact of maintenance immunosuppressive regimens--balance between graft protective suppression of immune functions and a near physiological immune responseRolf Weimer
Department of Internal Medicine, University of Giessen, Klinikstrasse 36, Giessen, Germany
Transpl Int 24:596-609. 2011....
- Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipientsDirk R J Kuypers
Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium
Clin Ther 30:673-83. 2008..In both studies, target mycophenolic acid (MPA) AUC(0-12 h) ranges (ie, values used to guide MMF dosing) were derived from a previous study ..
- Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic reviewSimon R Knight
Transplantation 85:1675-85. 2008..A number of factors interact to result in variability in blood levels of mycophenolic acid (MPA) increasing the risk of toxicity...
- Methanol-associated matrix effects in electrospray ionization tandem mass spectrometryThomas M Annesley
Department of Pathology, University of Michigan Health Sciences Center, Ann Arbor, MI, USA
Clin Chem 53:1827-34. 2007..Preliminary observations indicated that the methanol used in the mobile phase could be a source of differential ionization or ion suppression...
- Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetesPeter A Gottlieb
Barbara Davis Center for Childhood Diabetes, University of Colorado at Denver, Aurora, Colorado, USA
Diabetes Care 33:826-32. 2010..This trial tested whether mycophenolate mofetil (MMF) alone or with daclizumab (DZB) could arrest the loss of insulin-producing beta-cells in subjects with new-onset type 1 diabetes...
- Molecular basis for mycophenolic acid biosynthesis in Penicillium brevicompactumTorsten Bak Regueira
Department of Systems Biology, Technical University of Denmark, 2800 Kongens Lyngby, Denmark
Appl Environ Microbiol 77:3035-43. 2011b>Mycophenolic acid (MPA) is the active ingredient in the increasingly important immunosuppressive pharmaceuticals CellCept (Roche) and Myfortic (Novartis)...
- The RhoGDI-alpha/JNK signaling pathway plays a significant role in mycophenolic acid-induced apoptosis in an insulin-secreting cell lineYun Jong Park
The Research Institute for Transplantation, Yonsei University College of Medicine, Seoul, South Korea
Cell Signal 21:356-64. 2009b>Mycophenolic acid (MPA)-induced beta-cell toxicity is an important factor for islet graft function. The signal transduction mechanisms underlying this process have not been fully explored...
- Ex vivo modeling of the effects of mycophenolic acid on HIV infection: considerations for antiviral therapyRupinderjeet Kaur
Department of Medicine, Infectious Diseases, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390, USA
AIDS Res Hum Retroviruses 21:116-24. 2005Mycophenolate mofetil (MMF), the bioavailable form of mycophenolic acid (MPA), has been proposed as adjuvant therapy for human immunodeficiency virus type 1 (HIV-1) infection...
- Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantationGerhard Opelz
Department of Transplantation Immunology, University of Heidelberg, Heidelberg, Germany
Transplantation 87:795-802. 2009..There have been striking changes during the last 10 years concerning the choice of calcineurin inhibitor and antimetabolite agent prescribed after kidney transplantation...
- Increased expression of cytotoxic effector molecules: different interpretations for steroid-based and steroid-free immunosuppressionThomas Satterwhite
Department of Pediatrics, Stanford University School of Medicine, 269 Campus Drive, CCSR, Stanford, California 94305, USA
Pediatr Transplant 7:53-8. 2003....
- Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosisSander I van Leuven
Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Atherosclerosis 211:231-6. 2010..These changes include reduced inflammatory cell presence with a concomitant decrease in pro-inflammatory gene expression...
- Anti-DNA antibody induction of protein kinase C phosphorylation and fibronectin synthesis in human and murine lupus and the effect of mycophenolic acidSusan Yung
University of Hong Kong, Queen Mary Hospital, Hong Kong, China
Arthritis Rheum 60:2071-82. 2009..The effects of mycophenolic acid (MPA) on this pathway, and the effects of mycophenolate mofetil (MMF) treatment in (NZB x NZW)F(1)/J mice ..
- Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamideG Contreras
Division of Nephrology, Miller School of Medicine, University of Miami, Florida 33136, USA
Lupus 14:s33-8. 2005..Maintenance therapies with MMF or AZA following short-term CY induction in a sequential regimen are efficacious and safe for the treatment of high-risk patients with proliferative lupus nephritis...
- Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroidsM Buchler
Francois Rabelais University, Department of Nephrology and Clinical Immunology, Bretonneau Hospital, CHU Tours, France
Am J Transplant 7:2522-31. 2007..23%, p < 0.01). A CNI-free regimen using sirolimus-MMF can achieve excellent renal function, but patients on sirolimus experienced a high rate of adverse events and study drug discontinuation...
- Saccharomyces cerevisiae transcription elongation mutants are defective in PUR5 induction in response to nucleotide depletionR J Shaw
Department of Biochemistry, Emory University School of Medicine, Atlanta, Georgia 30322, USA
Mol Cell Biol 20:7427-37. 2000..An optimally functioning elongation machinery is critical for this response...
- Mycophenolate mofetil for ocular inflammationEbenezer Daniel
The Fundus Photograph Reading Center, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
Am J Ophthalmol 149:423-32.e1-2. 2010..To evaluate mycophenolate mofetil as a single noncorticosteroid immunosuppressive treatment for noninfectious ocular inflammatory diseases...
- The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipientsDirk R J Kuypers
Department of Nephrology and Renal Transplantation, Laboratory of Absorption and Digestion, University Hospitals Leuven, Belgium
Clin Pharmacol Ther 78:351-61. 2005b>Mycophenolic acid (MPA), an effective immunosuppressive drug used in renal transplantation, is extensively glucuronidated by several uridine diphosphate-glucuronosyltransferases (UGTs) into an inactive 7-O-glucuronide and, to a lesser ..
- The anti-fibrotic effect of mycophenolic acid-induced neutral endopeptidaseMaria Pia Dell'Oglio
Renal, Dialysis and Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy
J Am Soc Nephrol 21:2157-68. 2010b>Mycophenolic acid (MPA) appears to have anti-fibrotic effects, but the molecular mechanisms underlying this are unknown. We prospectively studied 35 stable kidney transplant recipients maintained on cyclosporine and azathioprine...
- Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year reportJ A Kobashigawa
University of California at Los Angeles, Los Angeles, CA
Am J Transplant 6:1377-86. 2006....
- Mycophenolic acid may delay allograft fibrosis by inhibiting transforming growth factor-beta1-induced activation of Nox-2 through the nuclear factor-kappaB pathwayArjang Djamali
Department of Medicine, University of Wisconsin Madison SMPH, Madison, WI, USA
Transplantation 90:387-93. 2010..We evaluated the role of renal tubular Nox-2 in the pathogenesis of epithelial-to-mesenchymal transition (EMT) in kidney allografts...
- Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetilM Mourad
Department of Kidney and Pancreas Transplantation, University Hospital Saint Luc, Universite Catholique de Louvain, Avenue Hippocrate, 10, 1200 Brussels, Belgium
Clin Chem 47:88-94. 2001..This study was designed to investigate the relationship between the clinical events and the pharmacokinetics of mycophenolic acid (MPA) in adult renal transplantation.
- A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantationB Bolwell
Department of Hematology and Medical Oncology, Department of Biostatistics and Epidemiology, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Bone Marrow Transplant 34:621-5. 2004....
- Mycophenolic acid attenuates tumor necrosis factor-alpha-induced endothelin-1 production in human aortic endothelial cellsWon Seok Yang
Division of Nephrology, Department of Internal Medicine, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Republic of Korea
Atherosclerosis 211:48-54. 2010..This study was conducted to evaluate the effect of mycophenolic acid (MPA), an immunosuppressant for the transplant recipients, on tumor necrosis factor-alpha (TNF-alpha)-..
- Influenza virus vaccination in kidney transplant recipients: serum antibody response to different immunosuppressive drugsMauro J C Salles
Clinical of Infectious Diseases, Department of Internal Medicine, Santa Casa of Sao Paulo School of Medicine, Sao Paulo, Brazil
Clin Transplant 24:E17-23. 2010..This study prospectively accessed the immune response to the inactivated influenza vaccine in renal transplant recipients receiving either azathioprine or mycophenolate mofetil (MMF). Side effects were investigated...
- Mycophenolic acid antagonizes the activation of cultured human mesangial cellsIsabelle Dubus
Unité INSERM 441 Avenue du Haut Lévêque, 33600 Pessac, France
Kidney Int 62:857-67. 2002..Mycophenolate mofetil (MMF), the precursor of mycophenolic acid (MPA), is currently used in organ transplantation and has been shown to be protective in clinical and ..
- Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patientsStefan Vitko
Institute of Clinical and Experimental Medicine, Praha, Czech Republic
Am J Transplant 5:2521-30. 2005..Renal dysfunction in everolimus cohorts necessitates close monitoring...
- Proteins identified as targets of the acyl glucuronide metabolite of mycophenolic acid in kidney tissue from mycophenolate mofetil treated ratsAbdul R Asif
Abteilung Klinische Chemie, Georg August Universitat, Robert Koch Strasse 40, D 37075 Gottingen, Germany
Biochimie 89:393-402. 2007Covalent binding of the acyl glucuronide (AcMPAG) metabolite of the immunosuppressant mycophenolic acid (MPA) to proteins is considered a possible initiating event for organ toxicity...
- Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantationJohn F Valente
Department of Surgery, Division of Nephrology, University Hospitals of Cleveland, Cleveland, OH, USA
Am J Transplant 3:1128-34. 2003....
- In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetilNina Roos
Institut National de la Santé et de la Recherche Médicale U697, Hopital Saint Louis, Pavillon Bazin, 1 avenue Claude Vellefaux, 75010 Paris, France
J Pharmacol Exp Ther 321:583-9. 2007..g., collagen production, extracellular matrix contraction, and cell migration. Such properties may contribute to the beneficial therapeutic effects of MMF against fibrotic lesions developing in systemic sclerosis or during GVHD...
- Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitisLucia Sobrin
Massachusetts Eye Research and Surgery Institute, Cambridge, Massachusetts 02142, USA
Ophthalmology 115:1416-21, 1421.e1. 2008..To evaluate the outcomes of treatment with mycophenolate mofetil in patients with scleritis and uveitis refractory to or intolerant of methotrexate...
- Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trialC Grootscholten
Division of Nephrology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
Kidney Int 70:732-42. 2006..At last follow-up, there were no differences in serum creatinine or proteinuria between the two groups. However, since our study lacked sufficient power, longer follow-up is needed to reveal putative differences...
- The immunosuppressant mycophenolate mofetil attenuates neuronal damage after excitotoxic injury in hippocampal slice culturesFaramarz Dehghani
Institute of Anatomy, Hospital of the Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt am Main, Federal Republic of Germany
Eur J Neurosci 18:1061-72. 2003..In conclusion, MMF inhibits proliferation and activation of microglia and astrocytes and protects neurons after excitotoxic injury...
- Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trialR S Gaston
University of Alabama at Birmingham, Birmingham, AL, USA
Am J Transplant 9:1607-19. 2009..More recent data indicate a relationship between mycophenolic acid (MPA) exposure in individuals and clinical endpoints of rejection and toxicity...
- Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodiumBruce Kaplan
Division of Nephrology, Department of Medicine, University of Florida College of Medicine, Gainesville, FL 32610 0224, USA
Clin Transplant 19:551-8. 2005Enteric-coated mycophenolate sodium (EC-MPS) (myfortic) is an advanced formulation delivering mycophenolic acid (MPA), designed to improve MPA-related upper gastrointestinal adverse events by delaying the release of MPA until the small ..
- Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysisJason Moore
Department of Nephrology and Kidney Transplantation, Renal Institute of Birmingham, University Hospital Birmingham, Edgbaston, Birmingham, United Kingdom
Transplantation 87:591-605. 2009..In an attempt to aid clarification, we conducted a systematic review and meta-analysis of randomized trials that assessed CNI sparing (minimization or elimination) with mycophenolate as sole adjunctive immunosuppression...
- Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantationMagdi Shehata
Transplant Unit, Nottingham University Hospital, City Hospital Campus, Hucknall Road, Nottingham, UK
Transpl Int 22:821-30. 2009..randomized trial has evaluated whether conversion from mycophenolate mofetil (MMF) to EC-MPS permits mycophenolic acid dose to be increased or gastrointestinal side-effects to be ameliorated...
- Herb-Drug Glucuronidation InteractionsReginald F Frye; Fiscal Year: 2011..project are to determine in healthy volunteers: 1) the effect of prolonged Ginkgo biloba administration on mycophenolic acid pharmacokinetics;and 2) the effect of green tea leaf extract administration on raloxifene pharmacokinetics...
- T and B cell Homeostasis After Induction Therapy in Kidney TransplantationFadi G Lakkis; Fiscal Year: 2013..induction to Thymoglobulin induction in patients receiving identical maintenance immunosuppression (mycophenolic acid + Tacrolimus + early corticosteroid withdrawal)...
- ANTITUMOR DRUG EFFECTS ON PHOSPHATIDYLINOSITIDE TURNOVERJOHANNA STOECKLER; Fiscal Year: 1990..Antimetabolites that deplete cellular GTP, i.e., selenazofurin and mycophenolic acid, or that form GTP analogs, i.e...
- Nanotherapeutics for combined immunesuppression in organ transplantationDANIEL ROBERT GOLDSTEIN; Fiscal Year: 2013..We hypothesize that co-encapsulation of the commonly employed immune suppressive medications rapamycin and mycophenolic acid into FDA- approved poly(lactic-co-glycolic acid) (PLGA) nanoparticles will prolong allograft survival and ..
- PURINE METABOLISM IN TRICHOMONAS AND GIARDIAC Wang; Fiscal Year: 2000..for comparison, our biochemical data on the parasite enzyme have already indicated an unusually high K1 for mycophenolic acid and identified Cys319 in the enzyme as the catalytic nucleophile...
- NOVEL COFACTOR ANALOGUES AS IMMUNOSUPPRESSANTSKrzysztof Pankiewicz; Fiscal Year: 2000..affinity towards IMPDH has been achieved by replacement of the nicotinamide riboside portion of NAD with mycophenolic acid (MPA) derivatives...
- Novel agents against West Nile Virus infectionsKrzysztof Pankiewicz; Fiscal Year: 2003..Among them, mycophenolic acid (MPA) was one of the most potent compounds...
- IMP DEHYDROGENASE FROM PNEUMOCYSTIS AS A DRUG TARGETSHERRY QUEENER; Fiscal Year: 2000..Two known inhibitors of IMPDH (mycophenolic acid and tiazofurin) are strong inhibitors of P...
- DESIGN, SYNTHESIS AND STUDY OF IMPD INHIBITORSWayne Anderson; Fiscal Year: 1993..b>Mycophenolic acid (MPA), a mould metabolite, is one of the most potent IMPD inhibitors known, however the phenolic hydroxyl in ..
- NOVEL BENZAMIDE RIBOSIDE ANALOGUES AS ANTICANCER AGENTSKrzysztof Pankiewicz; Fiscal Year: 2001..PROPOSED COMMERCIAL APPLICATION: Ribavirin (antiviral) and mycophenolic acid (immunosuppressant) are clinically used drugs that express their activity through inhibition of inosine ..
- Purine salvage in Cryptosporidium parvumMitchell Abrahamsen; Fiscal Year: 2005..parvum inosine monophosphate dehydrogenase (cplMPDH) was identified as a suppressor of mycophenolic acid sensitivity in a Toxoplasma gondii strain defective for HXGPRT, a key gene in the purine salvage pathway of ..
- NOVEL DIFFERENTIATION AGENTS AGAINST HUMAN LEUKEMIASKrzysztof Pankiewicz; Fiscal Year: 2000..PROPOSED COMMERCIAL APPLICATIONS: Ribavirin (antiviral) and mycophenolic acid (immunosuppressant) are clinically useful drugs expressing their activity due to inhibition of inosine ..
- BOTANICAL/DRUG INTERACTIONS IN HIV: GLUCURONIDATIONPhilip Smith; Fiscal Year: 2004..conjugative metabolic pathway important for the elimination of azidothymidine, abacavir, efavirenz,and mycophenolic acid. Glucuronidation is the major Phase II metabolic pathway, but is much less studied that oxidative metabolism...
- ACTIVATION OF CHEMOTHERAPEUTIC AGENTS IN LEUKEMIC CELLSDonna Shewach; Fiscal Year: 1992..corresponding deoxyribonucleoside, or depleted by incubating the cells with phosphonoacetyl-L-aspartate and mycophenolic acid, which are inhibitors of pyrimidine and purine biosynthesis, respectively...
- ARBOVIRUS REPLICATION IN MOSQUITO AND VERTEBRATE CELLSVictor Stollar; Fiscal Year: 1991..and have low levels of ado met, 2) SVmpa, which can grow in mosquito cells which have been treated with mycophenolic acid, and have low levels of GTP, 3) Svcp which shows increased cytopathogenicity for mosquito cells, 4) SVcl35 ..
- ROLE OF INTESTINAL UGT IN DRUG DISPOSITIONPhilip Smith; Fiscal Year: 2005..b>Mycophenolic acid (MPA, immunosuppressant) and SN-38 (antitumor), are active compounds derived from prodrugs MMF and ..
- HTLV Receptor Identification and CharacterizationLee Ratner; Fiscal Year: 2005..vector expressing drug resistance markers, and selection carried out sequentially with G418, puromycin, and mycophenolic acid. Selected cells will be screened with an HTLV envelope pseudotyped HIV vector expressing luciferase, and the ..
- VIRUSES, ACQUIRED IMMUNODEFICIENCY, AND KAPOSI'S SARCOMAMartin Hirsch; Fiscal Year: 1993..Rescue analysis will be assessed by use of selective markers (resistance to mycophenolic acid), polymerase chain reaction assays of secondarily infected fibroblasts, and detection of HIV-1 antigen ..
- Novel inhibitors of the replication of poxvirusesJohan Neyts; Fiscal Year: 2004..The final goal of this application is to advance a compound for the treatment of (systemic or cutaneous) poxvirus infections to the initial stages of development, i.e., selecting an IND candidate. ..
- Recurrence of T1D in Pancreas TransplantationGeorge Burke; Fiscal Year: 2009..The knowledge gained should also be relevant to islet cell transplantation and spontaneous disease. ..
- Pharmacokinetics & Genomics in Glomerular DiseasesMELANIE JOY; Fiscal Year: 2008..The selection of collaborators with expertise in the areas of this grant will enhance the career development of Dr. Joy. ..
- African American Study of Kidney Disease and Hypertensi*Gabriel Contreras; Fiscal Year: 2007..Such results might eventually lead to new strategies that delay or prevent ESRD. ..
- Visual outcomes & quality of life in CMV retinitisJennifer Thorne; Fiscal Year: 2006..abstract_text> ..
- Mycophenylate mofetil for treatment of chronic GVHDPaul Martin; Fiscal Year: 2008..unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
- Clinical Translational Research in Transplant NephrologyBryan Becker; Fiscal Year: 2006..It will also work to meet the NIH's goal of increasing the number of physician-scientists conducting high-quality patient-oriented research. ..
- Function & Fate of Alloantigen-specific CD8 Cell in GVHDPaul Martin; Fiscal Year: 2005..The studies proposed in this application will help clarify the critical functions and fate of specific donor CD8 cell population that cause GVHD. ..
- Regulation of GnRH Neuronal Development by FGF SignalingJohn Gill; Fiscal Year: 2005..Critical stages of GnRH neuron development will be evaluated in mice to discern the functional contribution of FGF signaling in this important neuroendocrine system. ..
- RENAL MEDULLARY NITRIC OXIDE AND BLOOD PRESSUREDavid Mattson; Fiscal Year: 2001....
- E M Transdifferentiation in Proximal Tubule CellsBryan Becker; Fiscal Year: 2004..abstract_text> ..
- Clonal Selection in Diabetic NephropathyOliver Lenz; Fiscal Year: 2003..The long-term goal of our proposal is to characterize the role of clonal selection in glomerular disease, and identify new targets for screening, prevention, and intervention in the pathogenesis of diabetic nephropathy. ..
- TEMPORALLY CONTROLLED DEPLETION OF ALLOREACTIVE T CELLSPaul Martin; Fiscal Year: 2002..Results of these preclinical studies will help to assess the potential risks and benefits of using similar approaches to prevent GVHD in human marrow transplantation. ..
- Angiotensin II Receptor Blockade and Chronic RejectionBryan Becker; Fiscal Year: 2003....
- OPTIMIZATION OF HUMAN FETAL PANCREAS FOR TRANSPLANTATIONHans Sollinger; Fiscal Year: 2001..The results of these studies will provide a sufficient source of HFP tissue for clinical transplantation which responds to glucose challenge and requires minimal immunosuppressive therapy. ..
- GBV-B: A SMALL PRIMATE MODEL FOR HEPATITIS C INFECTIONRobert Lanford; Fiscal Year: 2008..unreadable] [unreadable] [unreadable]..
- Resolution of Acute Hepatitis B Virus Infections in ChimpanzeesRobert Lanford; Fiscal Year: 2008..Our long-term objective is to apply our understanding of the resolution of acute HBV infection to the development of effective new immunotherapies for chronic HBV infections. [unreadable] [unreadable] [unreadable]..
- IMPDH as a Drug Target in CryptosporidiumBoris Striepen; Fiscal Year: 2008..This work will provide urgently needed molecular reagents to understand the biology of nutrient uptake and drug resistance in this unique parasite. [unreadable] [unreadable] [unreadable]..
- Jo-1-specific T Cell Responses in PolymyositisDANA ASCHERMAN; Fiscal Year: 2007..These studies are intended to also provide insight concerning the relative roles of altered T cell repertoire and antigen presentation in the expression of Jo-1+ polymyositis. ..
- Mechanisms of Innate and Adaptive Immunity In HCVDavid Nelson; Fiscal Year: 2009..A better understanding of the immunologic factors that determine resolution or persistence of the infection may help in the design of therapies and vaccines for the control of HCV infection. ..
- Repression of HIV Transcription: from mechanism to anti-latency therapiesDavid Margolis; Fiscal Year: 2007..abstract_text> ..
- Pathogenesis of Otitis Media with EffusionPatricia A Hebda; Fiscal Year: 2010..With these studies the investigators hope to elucidate the role of specific inflammatory signals and pathways in promoting disease persistence, and thus to identify potential targets for future therapeutic interventions. ..
- Astatine-211 Conditioning for Nonmyeloablative Hematopoietic Stem Cell AllograftsBRENDA MARIE SANDMAIER; Fiscal Year: 2010..The final, and most important, studies will involve determining the quantity of 211At-labeled MAb required to obtain stable engraftment in HCT involvingDLA- haploidentical littermates. ..
- Chicago Islet Consortium ICR at UICJose Oberholzer; Fiscal Year: 2008..In addition, and most importantly for the progres of the field, the ICR at UIC will continue to provide large numbers of high-quality islet preparations for transplantation in diabetic patients. ..
- Improving Platelet Recovery After RadiationGeorge Georges; Fiscal Year: 2008..unreadable] [unreadable] [unreadable] [unreadable]..
- Regulation of Mammalian Oocyte MaturationStephen Downs; Fiscal Year: 2007..Furthermore, these studies will benefit the development of in vitro systems where either meiotic arrest or completion of meiotic maturation is the desired endpoint. ..
- BIOSYNTHESIS OF SOME MICROBIAL METABOLITESRonald Parry; Fiscal Year: 2007..Future investigations of sparsomycin will focus on cloning the sparsomycin resistance gene from S. sparsogenes to understand the mechanism of self-resistance in this organism and to gain access to the biosynthetic genes. ..
- BIOSYNTHESIS AND METABOLISM OF CYCLOPENTANOIDSRonald Parry; Fiscal Year: 2001..The potential use of the CmaA gene for construction of hybrid peptide antibiotics containing L-alloisoleucine or coronamic acid will also be explored, using surfactin biosynthesis in B. subtilis as a model system. ..
- QUALITY OF LIFE AND COST EFFECTIVENESS IN CMV RETINITISJohn Kempen; Fiscal Year: 2002..Subanalyses will assess what factors other than treatment strategy are associated with improved QOL and cost-effectiveness. ..
- JCV Virus Expression in Oropharynx and HIVJoseph Berger; Fiscal Year: 2004..This line of investigation would add credence to an oropharyngeal mechanism of JCV transmission and may ultimately lead to the clinical identification of an acute illness attributable to this pathogen. ..
- Proteomic and mRNA Profiling of Urine and Urine SedimentBrad Rovin; Fiscal Year: 2004..abstract_text> ..
- Multi-site Trial of Azathioprine Dosing in Crohn DiseaseStephen Hanauer; Fiscal Year: 2004..Predictive models will be performed to assess responsiveness based upon initial and inducible TPMT activity and achievable 6-TGN and 6-MMPR metabolite based upon incremental AZA dosing. ..
- YEAST GENES INVOLVED IN GENERAL TRANSCRIPTIONAL CONTROLCLYDE DENIS; Fiscal Year: 2003..The key features of the ADH2 promoter which are responsive to the CCR4-NOT complex will be identified to determine how the CCR4-NOT complex controls the ADH2 gene in a positive manner. ..
- Gene Expression Analyses During IFN Antiviral TherapyRobert Lanford; Fiscal Year: 2005..These data will help determine why interferon therapy is often unsuccessful for chronic HCV infections and provide cellular targets for future therapies. ..
- Bone Marrow Angioblasts For Cardiac RegenerationSilviu Itescu; Fiscal Year: 2004....
- A cell-free system for exocytosis in the beta-cellSUSANNE STRAUB SHARP; Fiscal Year: 2005..physiological mechanisms such as time-dependent potentiation and biphasic insulin release. The method will also allow the study of some aspects of endocytosis. ..
- PEMPHIGUS 2005-PROGRESS AND FUTURE DIRECTIONSJean Claude Bystryn; Fiscal Year: 2005..We expect it will attract 100-150 scientists and clinicians dedicated to investigate and treating pemphigus. ..
- Cytokines for Immune Protection from Acute IrradiationGeorge Georges; Fiscal Year: 2005..The secondary endpoint is immune reconstitution. Upon study completion, we will have identified the optimal cytokine treatment and the highest dose of TBI that can be reliably survived without HSC support. ..
- Novel Therapies for Resistant FSGSHoward Trachtman; Fiscal Year: 2006..The infrastructure that is established for the performance of this R21/R33 project should prove useful for the efficient assessment of additional novel therapies that will be developed in the future for patients with primary FSGS. ..
- ICAM1 gene inactivation protects against ischemic injuryRobert Montgomery; Fiscal Year: 2006..This work has important implications for the selective inactivation of gene function in allografts through ex vivo gene transfer. ..
- Repression of HIV Transcription-A Pathway to QuiescenceDavid Margolis; Fiscal Year: 2006..abstract_text> ..
- Longitudinal Studies of Primary Biliary CirrhosisMARLYN MAYO; Fiscal Year: 2006..In addition, the correlation between each of the putative surrogate markers will be analyzed. The results of this analysis will then be used to design future clinical trials in the field of PBC. [unreadable] [unreadable]..
- Experimental Dysautonomia: Pathogenesis and TreatmentSteven Vernino; Fiscal Year: 2006..unreadable] [unreadable]..
- CHEMOKINE REGULATION IN IMMUNE COMPLEX RENAL DISEASEBrad Rovin; Fiscal Year: 2001..This information will likely suggest new directions for interventions to control renal inflammation. ..